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Epidemiological data on carbapenemase-producing Gram-negative bacteria on the African continent are limited. Here, we re-
port the identification of VIM-2-producing Pseudomonas aeruginosa isolates in Tanzania. Eight out of 90 clinical isolates of P.
aeruginosa from a tertiary care hospital in Dar es Salaam were shown to harbor blaVIM-2. The blaVIM-2-positive isolates belonged
to two different sequence types (ST), ST244 and ST640, with blaVIM-2 located in an unusual integron structure lacking the 3= con-
served region of qacE1-sul1.
Pseudomonas aeruginosa is an opportunistic pathogen associ-ated with a number of nosocomial infections. Carbapenems
(i.e., meropenem and imipenem) are often the treatment of choice
for infections caused by P. aeruginosa that is resistant to other
antipseudomonal -lactams (1). However, the emergence and
spread of acquired carbapenemases, particularly metallo--lacta-
mases (MBLs), among P. aeruginosa are threatening the usefulness
of carbapenems (2). Resistance to carbapenems in P. aeruginosa
can also occur due to impermeability, efflux mechanisms, and
other -lactamases, including overexpression of the chromo-
somal AmpC (3).
Several acquired MBLs have been identified in P. aeruginosa,
including the VIM, IMP, SPM, GIM, AIM, FIM, and NDM en-
zymes (2, 4). The genes encoding these MBLs are associated with
mobile genetic elements, such as insertion sequence common re-
gion (ISCR) elements, transposons, and plasmids, and as gene
cassettes in integron structures. The dissemination of the various
MBLs among P. aeruginosa isolates has been shown to occur in
many different genetic backgrounds (5). However, two major
clonal complexes (CC), CC235 and CC111, predominate, partic-
ularly with respect to the dissemination of VIM enzymes (5).
On the African continent, an increasing number of reports
indicates that MBL-producing, and in particular VIM-2-produc-
ing, P. aeruginosa is widespread in Africa. VIM-2-producing P.
aeruginosa isolates have been observed in Tunisia (6–8), Kenya
(9), the Ivory Coast (10), Algeria (11), and South Africa (12).
Further, reports have shown the import of P. aeruginosa with
VIM-2 from African countries (Ghana, Tunisia, and Egypt) into
Europe (13–15).
(Part of this study was presented at the 22nd European Con-
gress of Microbiology and Infectious Diseases, 31 March to 3 April
2012, London, United Kingdom.)
The aim of this study was to determine the occurrence and
molecular epidemiology of MBL-producing P. aeruginosa isolates
identified from clinical specimens at a tertiary hospital in Dar es
Salaam, Tanzania. This was a cross-sectional study conducted at
the Central Pathology Laboratory, Muhimbili National Hospital
(MNH), Dar es Salaam, Tanzania. MNH is the largest tertiary
health care facility in Tanzania and serves as a university teaching
and referral hospital to the population of Dar es Salaam and the
whole country. The study included 90 clinical isolates of P. aerugi-
nosa consecutively collected from May 2010 to July 2011. Dupli-
cate isolates were excluded from the study. Only isolates that were
tested locally with respect to antimicrobial susceptibility were in-
cluded. The low total numbers of P. aeruginosa isolates in the
study period reflect the lack of routine analysis of all isolates with
respect to antimicrobial susceptibility. The species identification
of P. aeruginosa was based on the production of characteristic
pigments, biochemical test results (oxidase production), and Vi-
tek 2 (bioMérieux). Antimicrobial susceptibility testing was ini-
tially performed on all isolates by disk diffusion (Oxoid). Isolates
resistant to imipenem and/or meropenem were further screened
for MBL production using the MBL Etest (imipenem  EDTA)
(bioMérieux) and an extended panel of Etests for MIC determi-
nation. The results from the antimicrobial susceptibility testing
were interpreted according to the clinical breakpoints from the
European Committee for Antimicrobial Susceptibility Testing
(EUCAST) (http://www.eucast.org/clinical_breakpoints/). The
antimicrobial agents tested included piperacillin-tazobactam, cef-
tazidime, aztreonam, imipenem, meropenem, gentamicin, tobra-
mycin, amikacin, ciprofloxacin, and colistin. The presence of
MBL genes was investigated by PCR, as described previously (16).
The molecular typing of the MBL-producing isolates was per-
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formed by serotyping, pulsed-field gel electrophoresis (PFGE),
multilocus sequence typing (MLST), and sequencing of the inte-
grons, as previously described (13, 15). The genomic localization
of blaVIM-2 was determined by I-CeuI PFGE, followed by Southern
blotting and hybridization with nonradioactive labeled blaVIM-2
and 16S rRNA probes. The study was carried out in accordance
with existing standard ethics guidelines. Ethical clearance was ob-
tained from the Senate Research and Publications Committee of
Muhimbili University of Health and Allied Sciences in Dar es Sa-
laam, Tanzania.
Of the 90 isolates, 30 (33%), 16 (18%), and 15 (16%) were from
the outpatient clinics, burn unit, and surgical ward, respectively.
The remaining isolates (33%) were from patients in the pediatric
ward (5 [5.6%]), medical ward (12 [13.3%]), intensive care unit (3
[3.3%]), ear, nose, and throat (3 [3.3%]), emergency medicine
department (2 [2.2%]), and the psychiatric ward (4 [4.4%]). Eight
isolates (8.9%) from pus (n  5) and blood (n  3) specimens
were carbapenem resistant (Table 1). All carbapenem-resistant
isolates were from children (0 to 10 years). Six of these children
were admitted in the burn unit, one was from the pediatric surgery
ward, and one child with an infected wound was in the psychiatric
ward.
All carbapenem-resistant isolates were phenotypically positive
(ratio  8 and phantom zone) for MBL production. PCR followed
by sequencing showed that the isolates harbored blaVIM-2. The
blaVIM-2-positive isolates showed broad-spectrum -lactam resis-
tance, except for against aztreonam (Table 1). All VIM-2 isolates
showed high-level resistance to carbapenems (MIC, 32 mg/li-
ter), except one strain that was intermediate susceptible to mero-
penem (MIC, 4 mg/liter). The reason for the lower MIC in this
isolate is likely to be due to lack of non--lactamase-mediated
resistance mechanisms (e.g., efflux mechanisms and/or reduced
permeability), since the isolate had a positive MBL Etest result, as
did the other isolates, indicating the expression of blaVIM-2. Core-
sistance or intermediate susceptibility was observed for the amin-
oglycosides, including gentamicin, tobramycin, and amikacin. All
isolates were susceptible to ciprofloxacin and colistin (Table 1).
The PCR assays performed for extended-spectrum -lactamases
(GES, PER, and VEB) and 16S rRNA methylases were negative in
all blaVIM-2-positive isolates (data not shown). The observed high
rate (100%) of MBL production among the carbapenem-resistant
isolates is surprising, since non--lactamase-mediated resistance
mechanisms are generally more prevalent (17). The reason for this
high rate is unclear, but carbapenems were introduced in the hos-
pital as late as 2010, and their use is limited due to high costs.
Consequently, the selective pressure due to carbapenem usage has
been limited, and MBL-producing clones might have emerged
before the selection of other non--lactamase-mediated carbap-
enem resistance mechanisms, such as efflux or impermeablity,
started to emerge. Ciprofloxacin was introduced for use in chil-
dren after the study period, which might explain the ciprofloxacin
susceptibility in the MBL-positive isolates.
The PFGE patterns showed four different pulsotypes (A1, A2,
A3, and B), with two isolates belonging to each type (Table 1).
Isolates belonging to pulsotype A1 (P3-66 and P3-76) and A2
(P3-70 and P3-72) were isolated from patients admitted to the
burn unit within a time period of 23 days, indicating nosocomial
spread. Nosocomial spread was also suspected for the isolates of
pulsotype B (P3-73 and P3-77), as these were isolated within a
5-day period, also in the burn unit, but 3 months before the
isolates of pulsotypes A1 and A2 were identified in the same unit.
The isolates belonging to pulsotype A3 (P3-74 and P3-75) were
isolated from patients admitted to different wards (psychiatric
and pediatric) and 2.5 months apart. MLST showed that ST244
corresponded to pulsotypes A1 to A3 and ST640 to pulsotype B
(Table 1). ST244 has been shown to be a global P. aeruginosa clone
identified in several countries, including Poland (18), Brazil (19),
Spain (20–22), South Korea (23), Bulgaria (24), the Czech Repub-
lic (25), Greece (26), Russia (27), and Libya (28). ST244 has been
associated with VIM-2 (22, 26, 27) and with extended-spectrum
-lactamases, such as PER-1 and VEB-1 (18, 24). eBURST analysis
(http://eburst.mlst.net/) of the P. aeruginosa MLST database (http:
//pubmlst.org/paeruginosa/) showed that ST244 is the founder of
CC244, with 18 single-locus variants, indicating that this is a glob-
ally dispersed CC of related isolates associated with antimicro-
bial resistance. ST640, on the other hand, is currently a single-
ton in the MLST database and has been described in the Czech
Republic (25). To our knowledge, this is the first time ST640
has been associated with VIM-2. None of the isolates were type-
able by serotyping.
The sequencing of the genetic structure of blaVIM-2 in four
isolates showed that blaVIM-2 was present as the second gene cas-
sette in an integron, along with aacA7, dhfrB5, and aacC-A5. In-
terestingly, the integron lacked the 3= conserved region (3=CS) of
qacE1-sul1 and harbored the tniC at the 3= end, which is charac-
teristic of Tn5090/Tn402 (29). The sequenced part of the integron





Antimicrobial susceptibility (MIC) (mg/liter)a
PFGE typeb STcTZP CAZ ATM IPM MEM GEN AMK TOB CST CIP
P3-66 Blood 128 64 8 32 32 32 32 16 1 0.125 A1 244
P3-70 Pus 128 64 8 32 32 32 16 16 1 0.25 A2 244
P3-72 Pus 128 64 8 32 32 32 16 16 1 0.125 A2 244
P3-73 Pus 64 64 2 32 4 64 32 32 2 0.25 B 640
P3-74 Pus 128 64 4 32 32 128 64 32 2 0.25 A3 244
P3-75 Pus 128 128 4 32 32 64 32 32 2 0.125 A3 244
P3-76 Blood 128 64 8 32 32 32 16 16 1 0.125 A1 244
P3-77 Blood 128 64 4 32 32 64 32 32 2 0.25 B 640
a TZP, piperacillin-tazobactam; CAZ, ceftazidime; ATM, aztreonam; IPM, imipenem; MEM, meropenem; GEN, gentamicin; AMK, amikacin; TOB, tobramycin; CST, colistin; CIP,
ciprofloxacin.
b PFGE, pulsed-field gel electrophoresis.
c ST, sequence type.
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was identical to previously described integrons in P. aeruginosa
from the United States (30, 31), Russia (GenBank accession no.
AM749810, AM749811, and DQ522233) (27), Taiwan (32), the
Ivory Coast (10), Malaysia (33), Sri Lanka (33), and in a P. aerugi-
nosa isolate identified in Norway associated with import from
Ghana (13). Also, the integrons were similar, with only a few nu-
cleotide differences, to an integron identified in India (GenBank
accession no. HQ005291), as well as an integron from India,
where the aacC-A5 gene cassette was exchanged with aacC6-II
(29). PCRs and sequencing of the PCR products showed the pres-
ence of orf6, tniB, and tniA further downstream of tniC at the 3=
end of the integron. In all isolates, blaVIM-2 probes hybridized with
16S rRNA probes on a similarly sized chromosomal fragment
(550 kb) but also separately on an 40-kb fragment (data not
shown). This observation indicates both the chromosomal and
plasmid locations of blaVIM-2. In addition to the identification of
the integron structure in ST244 and ST640, this genetic structure
has been identified in several other different genetic backgrounds
of P. aeruginosa, such as ST233 (13, 31), ST234 (27), ST235 (27,
33), and ST1488 (10), with wide geographical distribution. This
suggests that the integron is associated with mobile genetic struc-
tures facilitating horizontal transfer and dissemination, as previ-
ously suggested (29). Further studies should be performed to in-
vestigate the surrounding genetic structures and the transfer of
this integron in these different genetic backgrounds.
In conclusion, this study further confirms the global distribu-
tion of blaVIM-2 located in an unusual integron and in new ge-
netic P. aeruginosa backgrounds, emphasizing the requirement of
global surveillance to fully understand the mechanisms of dissem-
ination.
Nucleotide sequence accession numbers. The nucleotide ac-
cession numbers for the sequenced integrons have been registered
in GenBank with the accession numbers KC630980 to KC630983.
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